ORION Pharma Ltd. In Search of Excellence

ORION PHARMA LIMITED

Register Office: Orion House, 153-154 Tejgaon I/A, Tejgaon, Dhaka

UN-AUDITED FIRST QUARTERLY (Q1) FINANCIAL STATEMENTS

This is to inform you all concerned that the un-audited condensed consolidated financial statements of Orion Pharma Limited as on and for the 1st Quarterly (Q1) period ended on September 30, 2025 have been adopted by the Board of Directors in its meeting held virtually on November 15, 2025 at 4:00 p.m. The excerpts of the Financial Statements are as follows:

Particulars		September 30, 2025	September 30, 2024
Consolidated Earnings Per Share (EPS) - Q1	:	BDT (0.30)	BDT 0.24
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q1	:	BDT 0.65	BDT 1.85
\ / ~		September 30, 2025	June 30, 2025
Consolidated Net Asset Value (NAV) Per Share – Q1 (Including Revaluation Surplus)	:	BDT 89.86	BDT 86.09
Consolidated Net Asset Value (NAV) Per Share – Q1 (Excluding Revaluation Surplus)	:	BDT 82.09	BDT 78.34

The Detailed Financial Statements are also available in the Company's website: www.orionpharma.com

Sd/-**Md. Ferdous Jaman**Company Secretary